Search results
Results from the WOW.Com Content Network
Biogen and Belgian partner UCB said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in patients with the chronic disease, a surprise result after the drug ...
The oral drug, brepocitinib, did not meet the primary study goal of reduction in disease activity at week 52 in patients of SLE, in which the immune system that normally helps protect the body ...
A new treatment is being trialled for the autoimmune condition
Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus. [5] [7] It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β.
KOLO-TV produces the only midday newscast that runs from 11 a.m. to noon while also airing ABC World News Tonight at 6 p.m., instead at 5:30 or 6:30 p.m. KTVN also airs their network newscast at 6 p.m. while KRNV-DT is the only station to air its network newscast at 5:30 p.m.
KTVN is the only station in the Reno market to not have a midday newscast. KTVN airs the CBS Evening News at 6 p.m. and KOLO-TV also airs their national newscast at 6 p.m. while KRNV is the only station to air their national newscast at 5:30 p.m. KOLO-TV began competing with KTVN on the 4:30 a.m. newscast which debuted on October 13, 2014.
FDA news: Trump administration pauses communication from CDC, other health agencies FDA approval of Journavx comes after 2 drug trials. Journavx was evaluated in two random double-blind ...
Belimumab is primarily used in people with systemic lupus erythematosus. When it was introduced in 2011, it was the first new drug approved to treat lupus in 56 years. [8] Sales rose to $31.2 million in the first quarter of 2012. [37] The total cost for the first year of treatment with belimumab is $28,000. [38]